GSA Capital Partners LLP Buys Shares of 68,371 Shattuck Labs, Inc. $STTK

GSA Capital Partners LLP purchased a new position in shares of Shattuck Labs, Inc. (NASDAQ:STTK) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 68,371 shares of the company’s stock, valued at approximately $474,000.

Other large investors also recently modified their holdings of the company. Orbimed Advisors LLC purchased a new position in shares of Shattuck Labs during the third quarter valued at approximately $15,072,000. NEXTBio Capital Management LP bought a new position in Shattuck Labs in the 4th quarter worth about $11,497,000. Price T Rowe Associates Inc. MD bought a new position in shares of Shattuck Labs in the fourth quarter worth $7,031,000. T. Rowe Price Investment Management Inc. purchased a new position in Shattuck Labs in the 4th quarter worth approximately $4,945,000. Finally, Bank of America Corp DE raised its holdings in shares of Shattuck Labs by 2,968.2% during the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock valued at $2,705,000 after buying an additional 1,094,997 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Trading Up 3.9%

Shares of NASDAQ STTK opened at $7.53 on Friday. The firm’s 50-day moving average price is $6.75 and its 200-day moving average price is $6.07. The stock has a market capitalization of $755.71 million, a price-to-earnings ratio of -14.76 and a beta of 1.08. Shattuck Labs, Inc. has a 12-month low of $0.90 and a 12-month high of $8.33.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). On average, equities analysts predict that Shattuck Labs, Inc. will post -0.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on STTK. HC Wainwright dropped their target price on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Cantor Fitzgerald initiated coverage on shares of Shattuck Labs in a research report on Monday, April 27th. They set an “overweight” rating on the stock. JPMorgan Chase & Co. started coverage on shares of Shattuck Labs in a research note on Friday, July 24th. They set an “overweight” rating and a $10.00 target price on the stock. Wall Street Zen downgraded Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Leerink Partners started coverage on shares of Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 target price for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.12.

Insider Activity

In other news, insider Abhinav A. Shukla sold 23,365 shares of Shattuck Labs stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the sale, the insider directly owned 86,380 shares in the company, valued at approximately $611,570.40. The trade was a 21.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Clay B. Siegall acquired 62,500 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were acquired at an average price of $4.00 per share, with a total value of $250,000.00. Following the completion of the purchase, the director owned 318,608 shares in the company, valued at approximately $1,274,432. This trade represents a 24.40% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have sold 53,875 shares of company stock worth $379,305. 8.79% of the stock is currently owned by company insiders.

Shattuck Labs Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.